521 related articles for article (PubMed ID: 11006136)
21. [New observations support the significance of angiogenesis in myeloma].
Lundberg LG; Lerner R; Palmblad J
Lakartidningen; 2001 Nov; 98(45):4985-90. PubMed ID: 11816901
[TBL] [Abstract][Full Text] [Related]
22. Correspondence re: K. Neben et al., high plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7: 2675-2681, 2001.
Go RS; Horstman AL
Clin Cancer Res; 2002 Aug; 8(8):2750; author reply 2751. PubMed ID: 12171909
[No Abstract] [Full Text] [Related]
23. Lenalidomide in multiple myeloma.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
[TBL] [Abstract][Full Text] [Related]
24. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
[TBL] [Abstract][Full Text] [Related]
25. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
Hattori Y; Kakimoto T
Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105
[No Abstract] [Full Text] [Related]
26. Palliative oncology: thalidomide.
Prommer EE
Am J Hosp Palliat Care; 2010 May; 27(3):198-204. PubMed ID: 19843880
[TBL] [Abstract][Full Text] [Related]
27. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Rosiñol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Bladé J; Montserrat E
Cytokine; 2004 May; 26(4):145-8. PubMed ID: 15149630
[TBL] [Abstract][Full Text] [Related]
28. Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H
Ann Hematol; 2004 Jul; 83(7):467-70. PubMed ID: 14625789
[TBL] [Abstract][Full Text] [Related]
29. Thalidomide: when everything old is new again.
Nirenberg A
Clin J Oncol Nurs; 2001; 5(1):15-8. PubMed ID: 11899395
[TBL] [Abstract][Full Text] [Related]
30. [Thalidomide. Clinical trials in cancer].
Politi PM
Medicina (B Aires); 2000; 60 Suppl 2():61-5. PubMed ID: 11188934
[TBL] [Abstract][Full Text] [Related]
31. The thalidomide saga.
Melchert M; List A
Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
[TBL] [Abstract][Full Text] [Related]
32. [Role of thalidomide in the treatment of multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
[TBL] [Abstract][Full Text] [Related]
33. Novel biologically based therapies for myeloma.
Anderson KC
Cancer J; 2001; 7 Suppl 1():S19-23. PubMed ID: 11504280
[TBL] [Abstract][Full Text] [Related]
34. [Angiogenesis and endothelial cells in blood neoplasms].
Usnarska-Zubkiewicz L; Poreba M; Kuliczkowski K
Przegl Lek; 2006; 63(3):146-50. PubMed ID: 16969900
[TBL] [Abstract][Full Text] [Related]
35. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
[TBL] [Abstract][Full Text] [Related]
36. Diabetic foot disease in a patient with multiple myeloma receiving thalidomide.
Pitini V; Arrigo C; Aloi G; Azzarello D; La Gattuta G
Haematologica; 2002 Feb; 87(2):ELT07. PubMed ID: 11836184
[No Abstract] [Full Text] [Related]
37. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
39. Thalidomide: from teratogen to anti-angiogenic.
Grover JK; Vats K
Indian J Cancer; 2001 Mar; 38(1):22-32. PubMed ID: 14758882
[TBL] [Abstract][Full Text] [Related]
40. [Thalidomide--new prospective therapy in oncology].
Pałgan K; Pałgan I
Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
